TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 1.40E-7nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.00000270nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: <0.00100nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.00100nMAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μl of reduced serum medium containing 0.5% FBS. Place ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.00200nMAssay Description:Agonist activity at EP4 receptor expressed in HEK293 cells assessed as cAMP accumulationMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.00290nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.00300nMAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μl of reduced serum medium containing 0.5% FBS. Place ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.00700nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μL of reduced serum medium containing 0.5% FBE. Place ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0100nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0100nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0100nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0140nMAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μl of reduced serum medium containing 0.5% FBS. Place ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0162nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0190nMAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 μl of reduced serum medium containing 0.5% FBS. Place ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0200nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0200nMAssay Description:Agonist activity at human EP4 receptor by cAMP assayMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0210nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0230nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0300nMAssay Description:Agonist activity at human EP4 receptor by cAMP assayMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0300nMAssay Description:Agonist activity at human EP4 receptor by cAMP assayMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0350nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0380nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0380nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0400nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0400nMAssay Description:Agonist activity at human EP4 receptor by cAMP assayMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0400nMAssay Description:Functional activity at human EP4 receptorMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0470nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0500nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0500nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0590nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0590nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0590nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0630nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0650nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0750nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0790nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.0880nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in GalphaS-mediated CREB activation measured after 6 to 24 ...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataIC50: 44nM EC50: 0.100nMpH: 7.4 T: 2°CAssay Description:HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, EP3, or EP4 receptors were washed with TME buffer, scraped from the bot...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.100nMAssay Description:Agonist activity at EP4 receptor expressed in HEK293 cells assessed as cAMP accumulationMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.100nMAssay Description:Agonist activity at human prostaglandin EP4 receptorMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataIC50: 29nM EC50: 0.100nMpH: 7.4 T: 2°CAssay Description:HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, EP3, or EP4 receptors were washed with TME buffer, scraped from the bot...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.110nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 ul of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.142nMAssay Description:Agonist activity at human EP4 receptor expressed in HEK293T/17 cells assessed as increase in intracellular cAMP level incubated for 30 mins by ELISAMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.150nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.150nMT: 2°CAssay Description:1. Seed cells on an EP2 or EP4 STEP plate at a density of 40,000-80,000 cells/well in 200 uL of reduced serum medium containing 0.5% FBS. Place the p...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.200nMAssay Description:Agonist activity at human prostaglandin EP4 receptorMore data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataIC50: 5.5nM EC50: 0.200nMpH: 7.4 T: 2°CAssay Description:HEK-293 cells stably expressing the human or feline FP receptor, or EP1, EP2, EP3, or EP4 receptors were washed with TME buffer, scraped from the bot...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.200nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.200nMpH: 7.4 T: 2°CAssay Description:A 384-well drug plate was prepared to contain test compounds, PGE2 and cAMP in 16 serial dilutions in triplicate, using a Biomek station. HEK-EBNA ce...More data for this Ligand-Target Pair
TargetProstaglandin E2 receptor EP4 subtype(Homo sapiens (Human))
Cayman Chemical Company Inc
US Patent
Cayman Chemical Company Inc
US Patent
Affinity DataEC50: 0.200nMAssay Description:Functional activity at human EP4 receptorMore data for this Ligand-Target Pair
